Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha (evolocumab) ...

More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is to make ...

We're celebrating 25 years of work to advance a bold vision for a just and inclusive democracy and economy that reflects a growing and diversifying nation. Read Taifa Smith Butler's reflection on ...